Concord Wealth Partners’s Catalyst Pharmaceutical CPRX Stock Holding History

Concord Wealth Partners’s Portfolio CPRX Stock Details CPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$31	Buy	+1	New	+$30	﹤0.01%	877
2026 Q1	–	Sell	-1	Closed	-$23	–	311
2025 Q4	$23	Hold	1	–	–	﹤0.01%	839
2025 Q3	$20	Hold	1	–	–	﹤0.01%	824
2025 Q2	$22	Hold	1	–	–	﹤0.01%	853
2025 Q1	$24	Hold	1	–	–	﹤0.01%	803
2024 Q4	$21	Hold	1	–	–	﹤0.01%	916
2024 Q3	$20	Hold	1	–	–	﹤0.01%	950
2024 Q2	$15	Hold	1	–	–	﹤0.01%	830
2024 Q1	$16	Buy	+1	New	+$15	﹤0.01%	846

Other funds holding CPRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

GCL

Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Concord Wealth Partners's CPRX Position: Q2 2026 in Review

Concord Wealth Partners opened a new position in Catalyst Pharmaceutical (CPRX) in Q2 2026: 1 share worth $31. The stake represents ﹤0.01% of the portfolio and ranks #877 among its holdings. This is a return to the name: Concord Wealth Partners previously reported a position in CPRX as recently as Q4 2025.

Concord Wealth Partners first reported a position in CPRX in Q1 2024 and has held it in 9 quarters since. 396 funds tracked by Wall St. Rank hold CPRX as of Q2 2026.

Concord Wealth Partners held 1 share of Catalyst Pharmaceutical worth $31 as of Q2 2026.
Catalyst Pharmaceutical was a new Concord Wealth Partners position in Q2 2026.
Catalyst Pharmaceutical made up ﹤0.01% of Concord Wealth Partners's portfolio in Q2 2026, its #877 holding.
Concord Wealth Partners first reported a position in Catalyst Pharmaceutical in Q1 2024 and has held it in 9 quarters since.
396 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q2 2026.

Based on Concord Wealth Partners's 13F filing for Q2 2026, filed 27 Jul 2026.